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Abstract
Benign prostatic hyperplasia (BPH) and prostate carcinoma (CaP) are linked to aging and the presence of androgens,
suggesting that androgen regulated genes play a major role in these common diseases. Androgen regulation of prostate
growth and development depends on the presence of intact epithelial-stromal interactions. Further, the prostatic stroma is
implicated in BPH. This suggests that epithelial cell lines are inadequate to identify androgen regulated genes that could
contribute to BPH and CaP and which could serve as potential clinical biomarkers. In this study, we used a human prostate
xenograft model to define a profile of genes regulated in vivo by androgens, with an emphasis on identifying candidate
biomarkers. Benign transition zone (TZ) human prostate tissue from radical prostatectomies was grafted to the sub-renal
capsule site of intact or castrated male immunodeficient mice, followed by the removal or addition of androgens,
respectively. Microarray analysis of RNA from these tissues was used to identify genes that were; 1) highly expressed in
prostate, 2) had significant expression changes in response to androgens, and, 3) encode extracellular proteins. A total of 95
genes meeting these criteria were selected for analysis and validation of expression in patient prostate tissues using
quantitative real-time PCR. Expression levels of these genes were measured in pooled RNAs from human prostate tissues
with varying severity of BPH pathologic changes and CaP of varying Gleason score. A number of androgen regulated genes
were identified. Additionally, a subset of these genes were over-expressed in RNA from clinical BPH tissues, and the levels of
many were found to correlate with disease status. Our results demonstrate the feasibility, and some of the problems, of
using a mouse xenograft model to characterize the androgen regulated expression profiles of intact human prostate tissues.
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Introduction
Benign prostatic hyperplasia (BPH) is extremely common in aging
men, contributing to the pattern of morbidityknown as lower urinary
tract symptoms(LUTS) and resulting in significant annual healthcare
costs [1]. Despite the availability of medical and surgical treatments
for BPH there is still inadequate understanding of the processes
involved in benign pathological growth of the human prostate in vivo
[2]. Such information could serve to better predict which patients
may benefit from current medical therapy or are more likely to
progress to requiring surgical intervention, as well as inform the
choice of new medical approaches targeting novel pathways.
BPH occurs as men age, and androgens are required for the
development of the condition [3,4]. BPH is characterized patholog-
ically by glandular and stromal hyperplasia in the prostate transition
zone (TZ) [5]. The reawakening of the embryonic inductive potential
intheprostaticstromahasbeenproposedasacauseofBPH[3,5,6,7].
This is based on the idea that prostate growth results from the local
interplay of growth factors between the epithelial and stromal
elements of the organ under the influence of testicular androgens,
suggesting that androgen regulated genes play a major role in the
disease. This hypothesis is supported by considerable experimental
evidence in particular from tissue recombination models [8,9,10].
Prostatic inflammation has also been implicated in the
pathogenesis of BPH [11,12,13,14]. Inflammation is associated
with the severity of BPH, and the MTOPS (Medical Therapy of
Prostatic Symptoms) study suggests that the risk of BPH
progression and acute urinary retention is greater in men with
prostatic inflammation [13,15]. Increased prostate inflammation
may also result in the disruption of epithelial structure and
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antigen (PSA).
Prostatic growth, differentiation and adult function are
dependent upon the presence of androgens. It is well established
that androgens control growth and differentiation via mesenchy-
mal-epithelial interactions. In the adult prostate, androgens are
believed to act through the stromal androgen receptor (AR) to
maintain a growth-quiescent gland [16,17] and through the
epithelial AR to elicit the secretory differentiated function of the
prostatic epithelium [18]. In contrast to normal growth-quies-
cence, hyperplastic growth of glandular epithelium and stroma
within the transition zone in BPH represents changes in the
balance between cell division and death. BPH may thus
inappropriately recapitulate key events in prostatic developmental
biology. The mesenchymal and epithelial genes regulated by
androgens that are important in abnormal prostate growth in BPH
remain to be completely defined. Studies using high throughput
cDNA microarrays with androgen stimulated carcinoma cell lines
are unlikely to be relevant to either prostatic development or BPH.
Transformed epithelial cells in culture have a markedly different
phenotype, and associated proteome, from their in vivo counter-
parts. In addition such approaches do not allow for simultaneous
detection of key stromal cell genes or for genes that may
be modulated as a consequence of crucial epithelial-stromal
interactions.
More biologically relevant studies utilizing cDNA microarray
analysis of BPH tissues have been reported. Luo, et al. analyzed
the expression of 6,500 human genes in prostate cancer and BPH
tissues from patients undergoing radical prostatectomy or
transurethral resection of the prostate (TURP) [19,20]. A number
of genes were found to be consistently upregulated in BPH
compared to normal prostate. These included IGF1, IGF2, TGFB3,
BMP5, MMP2, COX2, and GSTM5. However, these studies used
tissues enriched for epithelial cells. As a result, the analyses could
have missed potentially crucial genes expressed predominantly in
stromal cells. These studies did not address whether any of the
patients had undergone prior androgen-ablation therapy. Ap-
proaches based on RNA extracted from tissues also do not allow
for direct manipulation of hormonal stimulation, limiting the
ability to more directly detect genes regulated by androgens, which
might serve as predictors of response to therapies targeting
androgenic stimulation or as novel targets for alternate drug
therapy in this androgen driven disease process.
In another relevant study, gene expression profiles in prostatic
stromal cells from different prostate zones were analysed,
comparing normal and diseased tissues [21]. A number of genes
were found to be differentially expressed between BPH stroma and
normal transition zone (TZ) stroma. While many potentially
important stromal genes were identified that may play a role in
BPH, these studies used isolated stromal cells cultured in vitro,
which would likely result in altered gene expression patterns from
those which would be seen in vivo.
In the present study we used oligonucleotide microarrays to
examine the expression of androgen regulated genes in benign
human prostate tissue growing as xenografts in severe combined
immunodeficient (SCID) mice [22]. This approach maintains the
biologically relevant interactions of epithelium and stroma as
occurs in vivo and allows for direct manipulation of androgens,
either by castration or hormonal supplementation of the host. The
resulting data set was then analyzed to identify relatively highly
expressed genes which were androgen regulated. In an effort to
identify potential biomarkers amenable to future blood-based
testing, emphasis was placed on genes whose products were known
or predicted to be extracellular. Expression of these genes was then
analyzed using qRT-PCR with cDNA pools derived from tissues
from patients with minimal, mild, moderate and severe BPH
pathology changes, or with CaP, to determine whether expression
correlated with disease status.
Materials and Methods
Ethics Statement
De-identified human prostate tissue samples were obtained from
the Vanderbilt Tissue Acquisition Core via the Department of
Pathology in accordance with Vanderbilt IRB protocols. All
patients signed informed consent approving the use of their tissues
for unspecified research purposes. All experiments involving
animals were conducted according to the Animal Welfare Act
and approved by the Vanderbilt Institutional Animal Care and
Use Committee. Animal care/welfare and veterinary oversight
was provided by the Vanderbilt Divison of Animal Care.
Histopathologic Analysis and Sample Selection
To determine the severity of BPH pathology changes for cases
utilized for RNA extraction, TZ areas affected by glandular and
stromal hyperplasia were outlined in whole mount sections from
radical prostatectomy (RP) samples obtained via the Department
of Pathology in accordance with Vanderbilt IRB protocols. TZ
volumes were determined by planimetry with a digitized graphics
tablet, in a manner identical to our routine determination of total
tumor volume in RPs [23,24,25]. Preference was given to cases
with small volume peripheral zone (PZ) tumors, so that any overall
prostate enlargement will be due to TZ enlargement and to reduce
the likelihood that hormonal metabolism potentially relevant to
BPH would be altered by large volume prostate cancer [26]. BPH
was categorized from 37 cases as minimal (min), mild, moderate,
or severe, based on the following criteria. Min/control: TZ volume
,4.5 cm
3, prostate wt ,34 g, No BPH nodules; Mild BPH: TZ
volume 4.5–8.99 cm
3 or prostate wt 34–44.99 g or BPH nodules;
Moderate BPH: TZ volume 9–16.99 cm
3 or prostate wt 45–
59.99 g and BPH nodules; Severe BPH: TZ volume $17 cm
3 or
prostate wt $60 g and BPH nodules. Prostate cancer tissues were
classified as moderately differentiated (Gleason scores 5–6) or
poorly differentiated (Gleason scores 8–9). Snap frozen fresh tissue
cores procured as described below were processed for RNA and
histology [27].
Sub-Renal Xenografting of Fresh Human TZ Samples and
Hormonal Ablation Strategies
De-identified human prostate tissue samples were obtained from
the Vanderbilt Tissue Acquisition Core via the Department of
Pathology in accordance with Vanderbilt IRB protocols. 6 mm
diameter cores obtained intraoperatively from fresh RP specimens
were procured from the right and left TZ and PZ from mid to base
and from mid to apex as described [27] and histologic analysis was
performed on frozen sections of full thickness cross sections. Cores
determined to contain normal TZ tissue were cut into pieces
approximately 2–3 mm in thickness and 4–6 pieces were then
xenografted beneath the renal capsules of adult male severe
combined immunodeficient (SCID) mice [C.B-17/IcrHsd-scid
mice (Harlan, Indianapolis, IN)]. TZ tissues from each of six
patients were xenografted into sets of 10 castrated SCID mice with
some groups of mice receiving tissue from two different patients
when available, grafted onto contralateral kidneys. Five mice from
each group were given sub-cutaneous implants consisting of a
2.5 cm length of silastic tubing (ID 1.98 mm x OD 3.18 mm, Dow
Corning, Midland, MI) containing 25 mg of testosterone (PCCA,
Houston, TX). The ends of the silastic tubing were sealed with
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of corn oil was added prior to sealing the tubing to facilitate
dissolution of the testosterone. After allowing the xenografts to
establish for one month, the implants were removed from the
testosterone supplemented mice, and 25 mg testosterone pellets
(produced with a Parr Pellet Press, model 2816 with 4.5 mm die,
Parr Instrument Company, Moline, IL) were implanted subcuta-
neously in the mice that had not received testosterone. Control
mice were sacrificed at the time of androgen addition or removal,
and the remaining mice from each group were sacrificed at 1, 3, 7,
and 14 days following androgen addition or removal. Harvested
xenografts were quickly dissected under magnification and snap
frozen in liquid nitrogen. Frozen tissues were stored at 280uC.
RNA Extraction and cDNA Microarrays
RNA extraction of snap-frozen TZ tissues and harvested
xenografts was performed using a modification of previously
described methods [27,28]. Briefly, RNA was extracted using
TRIzol (Life Technologies, Inc., Gaithersburg, MD), followed by a
second RNA isolation using RNeasy (Qiagen Inc., Valencia, CA)
with DNAse treatment. RNA samples were stored at 280uC.
RNA quality was analyzed by the Vanderbilt Microarray Shared
Resource (VMSR) using spectrophotometry (NanoDrop Technol-
ogies, Wilmington, DE) and bioanalysis (Agilent Technologies,
Santa Clara, CA). RNA samples of xenografts were submitted to
the VMSR for amplification (NuGen Systems, Inc., Traverse City,
MI) and labeling, followed by hybridization to microarrays printed
from the Human Release 2.0 OligoLibrary, (Compugen, San Jose,
CA), containing 28,830 unique genes from a total of 29,134 oligos.
The reference RNA was created by pooling RNA samples from
both castrate and androgen treated tissues from day zero control
mice.
Statistical Analysis of Microarray Data
Due to the considerable variation inherent in individual
patients, the time 0 for each tissue sample was used as the control
or reference sample rather than a standard reference sample across
the entire experiment. Data were normalized by Lowess using
GeneTraffic software (Iobion Informatics, La Hoya, CA) and
imported into GeneSpring (Agilent Technologies, Santa Clara,
CA) for subsequent analysis. Initially, only day 0 and day 14 time
points were considered, with genes that had at least a 1.5-fold
upregulation in the day 14 sample vs. day 0 selected, which yielded
5,679 genes/probes. An ANOVA analysis was used to identify
genes with significant differences in expression, with a P-value cut-
off of 0.05, indicating 284 expected false positive genes. A Welch t-
test was then used to identify genes with significant differences
(P-value less than 0.05) in expression between days 0 and 14 across
all tissue samples. This list was then filtered by signal expression
value, retaining the top 95% of signal dynamic range, yielding
784 genes/probes. This method of analysis was independently
performed for both the castrate and testosterone supplemented
data sets. All statistical analyses of microarray data were
performed by the VMSR.
Identification of Candidate Biomarker Targets
Potential candidate genes were systematically selected with
overlapping bioinformatics criteria, employing WebGestalt: 1)
androgen-regulated (1.5-fold or P#0.05 within our microarray
data), 2) expressed at significantly higher levels in the prostate
relative to other tissues (P#0.05 by hypergeometric test), and 3)
extracellular space or cell surface (Gene Ontogeny categories).
These criteria yielded a set of genes that included previously
validated biomarkers, including KLK3, ACPP, and MSMB. Several
additional genes known or suspected to be involved in BPH based
upon prior studies were ‘‘manually’’ included for further study:
IGF1, IGF1R, TGFB1, TGFB3, TGFBR1, and TGFBR2. A total of
84 gene targets (and the 18S rRNA housekeeping control gene)
were chosen for confirmation of expression in patient samples,
several assessed with redundant probes.
Real-Time qRT-PCR Confirmation
A TaqMan low density microfluidic array card, format 96a
(Applied Biosystems, Foster City, CA) was designed to assay
candidate genes from the microarray analysis and control genes,
for a total of 96 targets. 1 mg of total RNA was reverse transcribed
into single-stranded cDNA using High-Capacity cDNA Archive
kit (Applied Biosystems). Following cDNA synthesis, RNA was
degraded by alkaline hydrolysis, adjusted to neutral pH, and
cDNA purified by adsorption to silica gel (QIAquick PCR
Purification kit, Qiagen Inc.) and eluted in 64 ml of 10 mmol/L
Tris HCl (pH 8.5). cDNA quantities were measured spectropho-
tometrically (NanoDrop ND-1000, NanoDrop Technologies).
cDNA was diluted to 0.25 ng/ml in 1X TaqMan Universal PCR
Master Mix (Applied Biosystems), loaded into the microfluidic
card, sealed and centrifuged. Cards were then cycled on an ABI
Prism 7900HT sequence detection system, and data analyzed with
SDS 2.1 software (Applied Biosystems). After normalization to the
endogenous control, 18S rRNA, levels were expressed relative to
the control RNA pool calibrator (fold change). RNAs prepared
from each category of BPH tissues were pooled from 5–10
patients. Control RNA was pooled from patients with no
appreciable TZ expansion. The analysis included four replicates
for the mild and severe BPH pools, as well as the moderately
differentiated and poorly differentiated prostate cancer pools, and
eight replicates for the control and moderate BPH pools.
Immunohistochemical Staining
Human prostate tissue samples from the paraffin embedded
whole mount blocks from the 43 patients originally characterized
for BPH pathology severity and utilized for corresponding TZ
derived RNA were obtained from the Vanderbilt Tissue
Acquisition Core via the Department of Pathology and tissue
microarrays were generated by one of the authors (MPR). The
microarrays contained three 0.6 mm core samples, two from the
TZ and one from PZ away from the cancer involved area. Staining
of tissue sections was performed using a previously described
protocol [29]. Sections (5 mm) were cut and mounted on charged
glass slides. After deparaffinization and rehydration, the tissue
sections were subjected to antigen retrieval by heating in a
microwave for 10 minutes in Vector H-3300 antigen unmasking
solution (1:100; Vector Laboratories, Inc., Burlingame, CA). Slides
were then incubated in 0.3% hydrogen peroxide in methanol for
30 minutes at room temperature (RT), followed by a 1 hr
incubation in 5% goat serum in PBS at RT. Slides were incubated
with primary antibodies overnight at 4uC in 5% goat serum in
PBS. Antibodies used were a mouse monoclonal against TIMP2
(1:300, sc-21735, Santa Cruz Biotechnology, Santa Cruz, CA),
and rabbit polyclonals against FGF2 (1:500, sc-79, Santa Cruz
Biotechnology, Santa Cruz, CA), and SMOC1 (1:100, Atlas
Antibodies, Stockholm, Sweden). The slides were then washed and
incubated in a biotinylated secondary antibody (rabbit anti-mouse
or swine anti-rabbit, 1:300, DAKO, Carpinteria, CA) at RT for
60 min, washed in PBS extensively, then incubated in ABC-HRP
complex (Vector Laboratories) for 30 min. Bound antibodies were
then visualized by incubation with liquid 3,39-diaminobenzidine
tetrahydrochloride (DAKO). Slides were then rinsed extensively
in tap water, counterstained with hematoxylin, and mounted.
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Zeiss AX10 Imager.M1 microscope and AxioVision Release 4.6
software.
The immunostained slides were reviewed by a pathologist
(MPR) blinded to the BPH pathology severity of the case and
results expressed in a semi-quantitative manner. Percentage
staining was scored on a scale of 0 to 4, where 0=no staining,
1=less than 25%, 2=25% to 50%, 3=50% to 75%, and 4=75%
to 100%. The intensity of staining was scored on a scale of 1 to 3,
where 1=mild, 2=moderate, and 3=marked. For a sample
yielding no staining, the intensity score was also 0. When both
stromal and epithelial staining was present, scoring was done
separately. To calculate a protein expression index, the percentage
score was summed with the intensity score. The combined scores
were plotted for each BPH pathology category (minimal, mild,
moderate, severe BPH changes), and Kruskal-Wallis tests were
used to compare the combined scores across different disease
severity status.
Results
Androgen-Regulated Gene Expression Profiles in Human
Prostate Transition Zone
We profiled gene expression patterns from human prostate TZ
xenografts, following the addition or subtraction of testosterone.
Figure 1 illustrates the general scheme used for manipulation of
androgen levels in SCID mice harboring sub-renal capsule prostate
xenografts. Total RNA was prepared from harvested xenografts with
or without exposure to testosterone for 0, 1, 3, 7, and 14 days. A pool
made from equal amounts of RNA from day 0 castrate and intact
mouse xenografts was used as a standard reference. A total of 58
hybridizations were completed, which included samples from six
patients. Initial analysis indicated a high level (up to 10 fold) of patient-
to-patient variation in expression levels in known androgen regulated
genes such as KLK3 (PSA). In order to allow for this expected biologic
variability between individual patient tissues, each patient’s tissue
derived RNA samples were re-centered to that patient’s time 0
controls. For the primary analysis, two time points were considered,
days 0 and 14, yielding 5,679 genes with a 1.5 fold or greater increase
in expression. An ANOVA analysis was performed on these 5,679
genes, with a P-value cut-off of 0.05, which predicts 284 false positives.
Genes that had at least a 1.5-fold increase or decrease in expression in
the day 14 sample vs. day 0 were then filtered by signal expression
value, retaining the top 95% of signal dynamic range, yielding 784
genes. The microarray data have been deposited in NCBI’s Gene
Expression Omnibus [30] and are accessible through GEO Series
accession number GSE17862 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE17862).
Genes Up-Regulated by Androgens in Human TZ
Xenografts
Table 1 lists the top 45 genes that were up-regulated in response
to androgen, sorted by fold change (in descending order). The top
three genes, KLK3 (PSA), MSMB (beta-microseminoprotein), and
TMEPAI (transmembrane prostate androgen-induced protein)
were all previously well known to be regulated by androgens in
human prostate [31,32,33]. Several other genes identified as up-
regulated in human TZ xenografts by testosterone have also been
previously shown to be regulated by androgens. These include
TRPM8 (transient receptor potential melastatin member 8), a
putative prognostic marker and therapeutic target in prostate
cancer [34,35], ACPP (prostatic acid phosphatase) [36], SCGB1A1
(uteroglobin) [37], NDRG1 (N-myc downstream regulated gene 1)
[38], and CREB3L4 (cAMP responsive element binding protein
3-like 4) [39]. RNASEL has been reported as a candidate
hereditary prostate cancer gene [40]. Other genes identified that
have been reported as androgen-regulated or involved in BPH or
prostate cancer included PTGDS (prostaglandin D2 synthase),
FGFBP1 (fibroblast growth factor binding protein 1), KLK11
(kallikrein 11), CXCL5 (chemokine (C-X-C motif) ligand 5),
FKBP11 (FK506-binding protein 11) and TIMP1 (tissue inhibitor
of metalloproteinase 1).
TMEPAI (transmembrane prostate androgen-induced protein)
was the most highly expressed androgen-regulated gene identified.
Additional highly expressed, androgen-regulated genes included
KLK3 (PSA), MSMB (beta-microseminoprotein), ACPP (prostatic
acid phosphatase) and SCGB1A1 (uteroglobin).
Genes Up-Regulated in Response to Androgen
Withdrawal
Table 2 lists the top 45 genes that were up-regulated in response
to the withdrawal of androgen for 14 days, sorted by fold change
(in descending order). One of the genes identified, GLI1 is up-
regulated in mouse prostate following castration [41]. Another
gene identified with increased expression was ANNAT1 (annexin
1), which has been reported to decrease in androgen stimulated
prostate cancer compared with benign prostatic epithelium [42].
Quantitative RT-PCR Analysis of Human Prostate RNA
Pools
To further investigate the expression levels of androgen
regulated genes identified by microarray analysis, quantitative
RT-PCR analysis was performed on selected targets using RNA
pools derived from human prostate tissues. A major clinical need
Figure 1. Experimental scheme for addition or withdrawal of
testosterone in human prostate xenografts. TZ tissues from six
patients were xenografted beneath the renal capsules of castrated male
SCID mice (10 mice per patient). Five mice from each group were then
given sub-cutaneous implants containing 25 mg of testosterone. After
allowing the xenographs to establish for one month, the implants were
removed from the testosterone supplemented mice, and 25 mg
testosterone pellets were implanted in mice that had not received
testosterone. Control mice were sacrificed at the time of androgen
addition or removal, and the remaining mice from each group were
sacrificed at 1, 3, 7, and 14 days.
doi:10.1371/journal.pone.0008384.g001
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regarding BPH progression or that may predict response to
treatments, including 5 alpha reductase inhibitors. Secreted
proteins that can be readily measured in blood are particularly
attractive clinical targets. From the gene expression profiles in
hormone manipulated TZ xenografts, potential biomarkers were
systematically selected with overlapping bioinformatics criteria,
employing WebGestalt. Gene targets selected were 1) androgen-
regulated within our microarray data, 2) expressed at significantly
higher levels in the prostate relative to other tissues, and 3) known
or predicted to express secreted or cell surface proteins. These
criteria yielded a set of candidate genes (Table 3) that included
some previously known biomarkers, including KLK3, ACPP, and
MSMB, further validating our experimental approach. Other
Table 1. Genes induced in response to androgen supplementation, day 0 vs. day 14.
Accession no. Fold Change Symbol P-value Gene Name
NM_001648 14.27 KLK3 0.00048 prostate specific antigen
NM_002443 5.31 MSMB 0.0488 beta-microseminoprotein
NM_020182 5.09 TMEPAI .0.05 transmembrane prostate androgen-induced protein
AL049919 3.59 CUTL2 0.00761 cut-like homeobox 2
AY090780 3.35 LOC131368 .0.05 hypothetical protein LOC131368
NM_007281 3.25 SCRG1 0.0115 scrapie responsive protein 1
NM_144597 3.23 MGC29937 0.00971 hypothetical protein MGC29937
AF469196 3.22 NUDT10 0.0478 nudix-type motif 10
NM_024080 3.19 TRPM8 0.00903 transient receptor potential melastatin member 8
NM_014405 3.16 CACNG4 0.000776 voltage-dependent calcium channel gamma-4 subunit
NM_014244 3.15 ADAMTS2 0.00006 ADAM with thrombospondin motifs-2
NM_170601 3.12 CSE-C 0.00813 cytosolic sialic acid 9-O-acetylesterase homolog
NM_002212 3.06 EIF6 .0.05 Eucaryotic initiation factor 6
NM_003504 3.03 CDC45L 0.00298 CDC45-like
D17189 2.98 GOLGA3 0.00791 golgi autoantigen, golgin subfamily a, 3
NM_001099 2.96 ACPP 0.0168 prostatic acid phosphatase
AF086356 2.89 TMEM59 .0.05 transmembrane protein 59
NM_003104 2.87 SORD 0.00453 sorbitol dehydrogenase
NM_003357 2.86 SCGB1A1 0.000497 secretoglobin, family 1A, member 1 (uteroglobin)
NM_001082 2.85 CYP4F2 0.000759 cytochrome P450, family 4, subfamily F, polypeptide 2
NM_022137 2.76 SMOC1 0.00747 secreted modular calcium-binding protein 1
NM_006877 2.76 GMPR 0.000878 guanosine monophosphate reductase
NM_000180 2.73 GUCY2D 0.0136 guanylate cyclase 2D, membrane (retina-specific)
NM_002465 2.73 MYBPC1 0.0126 myosin binding protein C, slow type isoform 1
BC032412 2.72 MGC40574 0.021 MGC40574 protein
NM_022471 2.69 GMCL1L .0.05 germ cell-less homolog 1 (Drosophila)-like
NM_152284 2.68 SHAX3 0.000453 Snf7 homologue associated with Alix 3
NM_152590 2.67 FLJ36004 0.0232 hypothetical protein FLJ36004
NM_152351 2.66 SLC5A10 .0.05 solute carrier family 5, member 10
NM_014353 2.61 RAB26 .0.05 RAB26, member RAS oncogene family
NM_006096 2.59 NDRG1 0.0415 N-myc downstream regulated gene 1
AK024944 2.56 MED28 0.00285 mediator complex subunit 28
AF118078 2.55 PRO1848 0.00611 PRO1848
AB051448 2.53 KIAA1661 .0.05 KIAA1661 protein
U92012 2.52 PDS5A .0.05 PDS5, regulator of cohesion maintenance, homolog A
BC039353 2.49 TTLL1 .0.05 tubulin tyrosine ligase-like family, member 1
NM_052863 2.45 SCGB3A1 0.00228 secretoglobin, family 3A, member 1
NM_024980 2.44 GPR157 .0.05 G protein-coupled receptor 157
NM_130898 2.41 CREB3L4 0.00235 cAMP responsive element binding protein 3-like 4
NM_006820 2.41 IFI44L 0.0139 interferon-induced protein 44-like
NM_003027 2.40 SH3GL3 .0.05 SH3-domain GRB2-like 3
NM_021133 2.38 RNASEL .0.05 ribonuclease L
doi:10.1371/journal.pone.0008384.t001
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IGF1, IGF1R, TGFB1, TGFB3, TGFBR1, and TGFBR2. The
expression levels of these target genes were measured in RNA
pools prepared from TZ tissues designated as having mild,
moderate, and severe BPH changes, as well as moderately and
poorly differentiated prostate cancer. RNA for each category of
Table 2. Genes induced in response to androgen withdrawal, day 0 vs. day 14.
Accession no. Fold Change Symbol P-value Gene Name
L19363 5.09 0.00151 radioresistant malignant melanoma cDNA
NM_015161 4.20 ARL6IP 0.0345 ADP-ribosylation factor-like 6 interacting protein
NM_007018 4.17 CEP1 0.024 centrosomal protein 1
NM_033337 4.17 CAV3 0.00936 caveolin 3
AK090628 4.09 0.00654 Neuroglioma cDNA
NM_000259 4.05 MYO5A 0.0195 myosin VA (heavy polypeptide 12, myoxin)
AK058128 3.49 0.0148 testis cDNA
NM_000700 3.48 ANXA1 0.00759 annexin I
NM_013278 3.35 IL17C 0.0164 interleukin 17C
BC015390 3.31 0.0205 unknown (protein for IMAGE:4403366)
NM_003758 3.09 EIF3S1 0.0369 eukaryotic translation initiation factor 3, subunit 1 alpha
NM_005042 3.07 PRH2 0.0317 proline-rich protein HaeIII subfamily 2
NM_020191 3.01 MRPS22 0.0288 mitochondrial ribosomal protein S22
NM_020403 2.97 PCDH9 0.0394 protocadherin 9 isoform 2
AY090737 2.96 CNTN4 0.00783 contactin 4
BQ025872 2.94 MYO9A 0.0267 myosin IXA
NM_005269 2.88 GLI 1 0.0202 glioma-associated oncogene homolog 1
NM_001938 2.86 DR1 0.0197 down-regulator of transcription 1
NM_080387 2.85 CLECSF8 0.0456 C-type lectin, superfamily member 8
AL833691 2.83 AFF3 0.0195 AF4/FMR2 family, member 3
NM_018365 2.83 MNS1 0.042 meiosis-specific nuclear structural protein 1
AK056076 2.81 FLJ31514 0.00423 hypothetical protein
AL832652 2.79 DNAH17 0.0269 dynein, axonemal, heavy chain 17
NM_152390 2.79 TMEM178 0.0329 transmembrane protein 178
BF111085 2.79 SOX1 0.0387 SRY (sex determining region Y)-box 1
NM_012311 2.78 KIN 0.047 HsKin17 protein
AF086063 2.77 BCL2 0.0119 B-cell CLL/lymphoma 2
NM_080629 2.74 COL11A1 0.0364 alpha 1 type XI collagen isoform A
AF324830 2.73 LIR9 0.0377 leukocyte Ig-like receptor 9
AB033091 2.71 SLC39A10 0.0495 solute carrier family 39 (zinc), member 10
BC033949 2.68 0.022
NM_003704 2.62 C4orf8 0.028 res4-22 protein
NM_004934 2.61 CDH18 0.0161 cadherin 18, type 2
NM_014221 2.60 MTCP1 0.0367 mature T-cell proliferation 1
NM_025170 2.57 DEPDC2 0.0114 DEP domain containing 2
NM_007072 2.56 HHLA2 0.0262 HERV-H LTR-associating 2
NM_014574 2.52 STRN3 0.0267 striatin, calmodulin binding protein 3
NM_015102 2.52 NPHP4 0.0194 nephronophthisis 4
NM_013943 2.51 CLIC4 0.0483 chloride intracellular channel 4
NM_017653 2.40 DYM 0.00184 dymeclin
NM_147175 2.39 HS6ST2 0.0196 heparan sulfate 6-O-sulfotransferase 2
NM_025140 2.33 CCDC92 0.0368 coiled-coil domain containing 92
NM_052946 2.31 NOSTRIN 0.00289 nitric oxide synthase trafficker
NM_005108 2.29 XYLB 0.00043 xylulokinase homolog
NM_025208 2.27 PDGFD 0.0444 platelet derived growth factor D
doi:10.1371/journal.pone.0008384.t002
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Symbol Fold Increase T14 P Increase T14 Fold Decrease C14 P Decrease C14 Cell surface? Over Expr in Prostate?
CART 1.91 YY
FGFBP1 2.05 0.0165 Y Y
SGCD 1.70 YY
EMP3 1.99 0.0171 Y Y
KLK11 1.92 0.0392 Y Y
ACPP 2.96 0.0168 Y Y
ALCAM 1.65 YY
ANK1 0.0219 Y Y
CHRNB1 0.0292 Y Y
CNFN 1.67 0.00136 Y Y
CNTNAP2 2.01 0.0151 Y Y
EFEMP2 1.69 0.00255 Y Y
F10 1.98 0.00321 Y Y
F11R 0.59 Y Y
FBN1 0.0223 Y Y
GABRG2 1.56 YY
HS3ST4 1.52 YY
IGF2 YY
IGF2R 0.017 Y Y
IHH 1.55 YY
KLK3 14.27 0.00048 Y Y
LIPG 1.76 YY
MGP 0.59 Y Y
MSMB 5.31 0.0488 Y Y
SCGB1A1 2.86 0.000497 Y Y
SCGB3A1 2.45 0.00228 Y Y
SEMA4F 2.03 YY
SGCA 1.53 0.0161 Y Y
SLC26A2 1.53 YY
SMOC1 2.76 0.00747 0.57 Y Y
STEAP 1.58 YY
TMEPAI 5.09 YY
WNT5B 1.56 0.00478 Y Y
HIST1H2AE 1.55 0.0138 Y
MAP2K5 1.64 0.0297 Y
RPS6KA2 1.53 Y
HIPK2 1.58 0.0372 Y
RBM42 0.000721 Y
AP1B1 1.54 0.00222 Y
C9orf61 1.97 0.0115 Y
COMT 1.59 0.0295 Y
COX5B 0.00132 Y
CPNE4 2.18 0.033 0.42 Y
CTTN 1.62 0.00328 Y
CYP1B1 1.94 0.0452 0.32 0.0289 Y
DAP13 0.0417 Y
PAAF1 0.63 Y
FLJ22795 2.08 Y
GABARAP 0.0358 Y
MAOA 1.88 0.0124 Y
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samples. Control RNA was pooled from TZ samples from patients
with no appreciable TZ expansion from glandular and stromal
hyperplasia.
The results of the qRT-PCR analyses are shown in Table 4.
RNA expression levels were determined for 86 candidate
biomarker genes. Of these, 72 genes were determined to have a
greater than 6-fold higher level than the normal control pool in at
least one of the BPH or prostate cancer pools. Relative to the
control prostate RNA pool, the average levels in the BPH or
prostate cancer RNA pools with expression levels ,1-fold were
designated as ‘‘low’’, 1- to 6-fold were designated as ‘‘moderate’’,
and .6-fold were designated as ‘‘high’’. Based on these criteria,
each gene was assigned to one of six categories (Table 4). Fifteen
genes were high in both BPH and prostate cancer, 41 genes were
high in BPH and moderate in prostate cancer, two genes were
high in BPH and low in prostate cancer, and five genes were
moderate in BPH and high in prostate cancer. No genes were
found that were classifiable as ‘‘low’’ in BPH.
Candidate BPH Biomarker Genes
A number of genes had expression levels in the BPH pools that
increased with severity of disease. Some of the genes had
expression levels that were particularly elevated in BPH, but
relatively lower in the prostate cancer pools. These genes would be
expected to have the best potential as candidate BPH biomarkers,
Symbol Fold Increase T14 P Increase T14 Fold Decrease C14 P Decrease C14 Cell surface? Over Expr in Prostate?
MARCKS 0.65 Y
FRMD5 1.63 0.00218 Y
NDUFA2 0.0358 Y
NME2 0.00538 0.65 Y
NMES1 1.94 Y
PSMB4 0.00151 Y
RNASEL 2.38 0.10 0.0412 Y
RPL30 0.64 Y
RPLP2 0.0412 Y
RPS26 0.55 Y
S100A11 0.0204 Y
S100A6 0.0443 Y
SEC24B 0.63 Y
SELM 1.57 0.0347 Y
SSR4 1.94 0.000199 Y
TXN2 0.0221 Y
TXNDC9 1.89 Y
VKORC1 1.55 Y
CDH13 0.52 Y
ALG10 1.57 Y
COL4A5 1.63 Y
FGF2 0.47 Y
RTN3 0.62 Y
TGFB2 1.54 Y
TIMP2 0.55 Y
RARB 0.62
UGCG 0.66 N, Y?
FUZ 2.01 N, Y?
IGF1 Y
IGF1R Y
TGFB1 Y
TGFB3 Y
TGFBR1 Y
TGFBR2 Y
18S rRNA
Potential candidates from our microarray results (androgen-regulated $1.5-fold or P#0.05) were combined with systematically selected genes using overlapping
bioinformatics criteria, employing WebGestalt. T14=testosterone, day 14 and C14=castrate, day 14.
doi:10.1371/journal.pone.0008384.t003
Table 3. Cont.
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from BPH and prostate cancer.
Category Gene Mild Mod Sev CaP BPH/CaP
Low in Prostate Cancer
Mod in BPH SCGB1A1 4.7 0.4 1.4 0.1 15.5
SCGB3A1 2.4 0.4 0.5 0.1 13.8
MGC14161 1.5 0.7 1.0 0.5 2.3
High in BPH SMOC1 12.0 10.7 17.7 0.5 25.9
S100A6 9.1 6.7 8.0 0.6 13.2
Moderate in Prostate Cancer
Mod in BPH TGFBR1 4.8 5.1 6.1 2.5 2.1
F11R 6.8 3.3 7.2 3.4 1.7
DAP13 2.7 3.9 4.9 2.8 1.4
PSMB4 2.1 1.5 2.5 1.5 1.4
RTN3 6.0 5.6 6.1 4.5 1.3
VKORC1 5.4 5.0 4.8 3.8 1.3
ALG10 4.6 3.6 4.6 4.4 1.0
IHH 5.6 1.4 6.5 5.3 0.9
RPS26 4.0 3.0 2.5 3.6 0.9
SLC26A2 3.6 2.4 4.7 5.4 0.7
ALCAM 4.0 2.5 3.1 5.3 0.6
CART 0.7 0.3 1.5 2.3 0.4
CYP1B1 2.5 1.4 2.0 4.6 0.4
High in BPH IGF2 32.9 16.3 39.8 1.6 18.1
F10 21.1 11.0 18.5 1.0 16.6
TGFB3 12.3 15.3 18.6 1.1 14.7
FGFBP1 24.6 1.6 10.6 1.2 10.2
FGF2 8.5 9.9 11.3 1.1 9.2
EMP3 9.8 7.3 10.1 1.0 8.7
SGCA 4.5 12.6 7.4 1.1 7.8
IGF1 20.2 20.7 31.7 3.7 6.6
TGFBR2 14.2 9.0 11.4 2.0 5.8
LIPG 24.2 10.4 40.7 4.6 5.4
TIMP2 9.6 11.6 11.9 2.1 5.3
RARB 14.0 7.2 11.4 2.2 5.0
RARB 7.0 4.9 5.4 1.3 4.5
EFEMP2 8.6 7.5 6.3 1.6 4.5
SGCD 4.8 7.9 9.0 2.0 3.7
RNASEL 9.2 6.3 9.7 2.3 3.6
SELM 6.9 6.9 7.3 2.0 3.6
COL4A5 9.1 5.9 10.7 2.6 3.3
TGFB1 12.1 9.0 8.8 3.3 3.1
CDH13 10.5 7.1 10.3 3.1 3.0
CHRNB1 9.1 6.7 10.5 2.9 3.0
ACPP 6.5 5.6 16.6 3.2 2.9
TGFB2 4.1 6.7 7.3 2.2 2.8
MGP 6.5 13.8 11.8 4.2 2.6
SEMA4F 12.6 9.1 15.1 4.8 2.5
UGCG 8.8 7.6 9.0 4.1 2.4
TGFB2 4.2 6.4 5.2 2.3 2.3
WNT5B 12.0 7.2 10.9 4.6 2.2
Category Gene Mild Mod Sev CaP BPH/CaP
COMT 11.4 7.3 13.7 5.3 2.1
MSMB 2.7 4.1 11.7 3.0 2.1
SEC24B 8.3 6.1 9.9 4.1 2.0
AP1B1 8.3 6.5 14.0 5.0 1.9
MARCKS 9.5 9.4 14.5 5.9 1.9
MSMB 1.7 2.6 8.6 2.3 1.9
COX5B 7.6 6.9 12.1 4.9 1.8
NDUFA2 6.9 5.5 13.1 4.6 1.8
FLJ11848 6.1 5.5 6.6 3.6 1.7
RPS6KA2 7.7 7.1 12.0 5.4 1.7
IGF2R 6.3 5.4 11.4 4.8 1.6
MAP2K5 8.2 8.6 8.3 5.1 1.6
CTTN 6.9 4.8 8.8 4.5 1.5
GABARAP 7.6 5.7 7.4 5.2 1.3
S100A11 8.0 4.3 7.6 5.1 1.3
IGF1R 5.4 3.5 9.8 5.3 1.2
High in Prostate Cancer
Mod in BPH NME1 6.9 4.4 6.6 7.8 0.8
CPNE4 3.3 3.5 8.5 7.2 0.7
STEAP 4.2 2.9 6.5 6.6 0.7
C9orf61 4.3 3.9 6.6 9.0 0.5
NMES1 4.8 1.2 4.4 18.1 0.2
High in BPH MGC10433 13.5 11.7 16.6 6.6 2.1
TXN2 9.8 7.9 11.7 6.6 1.5
FLJ22688 14.4 6.9 10.4 7.8 1.4
RPL30 13.3 9.6 14.1 10.5 1.2
SSR4 7.1 6.0 10.7 6.4 1.2
MAOA 9.6 4.3 9.4 6.9 1.1
TMEPAI 7.5 8.6 17.7 10.0 1.1
HIST1H2AE 6.5 5.6 8.7 6.7 1.0
RPLP2 8.1 5.6 7.4 6.9 1.0
HIPK2 8.4 7.5 11.5 10.4 0.9
KLK3 3.3 4.9 13.3 7.7 0.9
CNTNAP2 4.2 10.9 12.6 12.7 0.7
FLJ22795 12.0 6.2 9.8 13.1 0.7
HS3ST4 7.1 4.0 12.2 10.6 0.7
KLK11 14.2 8.6 9.1 17.0 0.6
KLK11 9.9 4.6 5.2 16.9 0.4
KLK3 7.0 7.1 22.5 30.7 0.4
Comparison between gene status in BPH and prostate cancer. BPH
categories are mild, moderate (Mod), and severe (Sev) and prostate
cancer (CaP) pools are derived from both moderately and poorly
differentiated tissues. Average expression levels ,1-fold were defined as
‘‘low’’, levels .6-fold were defined as ‘‘high’’, and levels between 1-fold
and 6-fold were defined as ‘‘moderate’’. Expression levels are relative to
a control pool derived from TZ samples from patients with no
appreciable TZ expansion. Genes that appear twice were measured
using two distinct primer sets. BPH/CaP is the ratio of the average
levels in the BPH pools divided by the average levels in the prostate
cancer pools.
doi:10.1371/journal.pone.0008384.t004
Table 4. Cont.
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expressed extracellularly and with an average expression level
at least three-fold greater in BPH RNA pools than in the pros-
tate cancer RNA pools included: CDH13, CHRNB1, COL4A5,
EFEMP2, EMP3, F10 (16-fold), FGF2, FGFBP1 (10-fold), IGF1,
IGF2 (18-fold), LIPG, RARB, SGCA, SGCD, TGFB1, TGFB3 (14-
fold), TGFBR2 and TIMP2 of the ‘‘high in BPH, moderate in
prostate cancer’’ group; SMOC1 (26-fold) in the ‘‘high in BPH, low
in prostate cancer’’ group; and SCGB3A1 (15-fold) and SCGB1A1
(14-fold) in the ‘‘moderate in BPH, low in prostate cancer’’ group.
Immunohistochemical Staining for Select Gene Targets in
Pathology-Characterized BPH Tissues
To determine if the differences in the RNA expression levels
observed in BPH tissues were also present at the protein level and to
further characterize the epithelial and/or stromal localization of
potential increased expression, we performed immunohistochemis-
try (IHC) on a BPH tissue microarray (TMA). The array contained
129 tissue sections from 43 unique patients, containing BPH tissues
with pathologies ranging from minimal to severe as defined in
Materials and Methods. FGF2, SMOC1 and TIMP2 were chosen for
IHC testing, as these genes had markedly increased RNA
expression levels in BPH relative to controls, and antibodies were
available that produced specific and satisfactory staining of human
TZ tissues. Representative immunostaining for each antibody is
shown in Figure 2. TIMP2 immunostaining was observed
predominantly in stromal cells, while FGF2 and SMOC1 staining
was observed in both stromal and epithelial cells. The immuno-
staining for TIMP2, FGF2, and SMOC1 was often quite marked.
Additionally,we immunostainedsome largerconventionalhistology
sections of BPH tissue using all three antibodies, and observed that
the staining was frequently focal and variable (data not shown),
compatible with observations made with TMA slides.
To more objectively analyze immunostaining results and allow
for statistical analysis, immunoreactivity on TMA sections was
scored semiquantitatively as described in the Materials and
Methods section. On the scale of 0–7 for combined extent and
intensity, the majority of samples that had duplicate TMA core
sections to assess had scores for individual sections separated by at
most 1 as shown in Table 5, and the average score for duplicate
sections was used for each case for statistical purposes. As shown in
Figure 3, none of the three examined proteins were found to be
significantly associated with BPH pathology severity based on this
limited IHC analysis. Kruskal-Wallis tests for overall difference
yield P-values ranging from 0.10 to 0.96.
Discussion
There is a need for BPH-specific markers that correlate with
diseaseprogression,which could be used fortheearlyidentificationof
patients likely to progress to more severely symptomatic disease. The
timely use of existing or novel non-surgical therapies in these patients
mayreducethesignificantcostandmorbidityofsurgicalintervention.
Hyperplastic growth of the prostate transition zone associated with
clinical BPH may be the result of the abnormal expression of key
androgen responsive genes, including those involved in prostatic
development, and which lead to an imbalance between cell division
and cell death. Although several candidate mediators have been
suggested to play a role in BPH, the androgen regulated genes that
are important for both normal and abnormal prostate growth remain
Figure 2. Immunohistochemical staining for FGF2, SMOC1, and TIMP2 in BPH samples with different degrees of severity. Tissue
sections are ,0.6 mm in diameter. FGF2 and SMOC1 staining was observed in both stromal and epithelial cells while TIMP2 staining was present
predominantly in stromal cells.
doi:10.1371/journal.pone.0008384.g002
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regulated by androgens in human transition zone prostate tissue in
vivo. The expression of a subset of these genes was correlated at the
RNA level with disease status in BPH tissues.
A subset of these genes was investigated at the protein level by
IHC. Expression in epithelium and/or stroma was confirmed in
tissues of varying severity BPH pathology. However, no obvious
correlation was seen between IHC intensity and BPH pathology
severity. This panel of genes provides a valuable dataset for
androgen regulated genes that could be etiologically involved in
the abnormal epithelial and stromal proliferation characteristic of
BPH. Future investigation will be necessary to establish the
biologic significance of specific genes in the evolution of BPH and
the possible suitability as a target for pharmacologic intervention.
It is desirable to have biomarkers of clinical utility in BPH prior to
acquisition of tissue as a consequence of therapeutic intervention
(e.g., TURP or suprapubic prostatectomy). As such, tissue based
quantitation of mRNA levels or IHC intensity is unlikely to be a
clinically useful test. Our studies provide a candidate list for further
investigation using more suitable test substrates, such as urine for
mRNA or protein or serum for protein. The highly relevant model
of androgen regulated expression in intact TZ tissues analogous to
actual BPH tissues increases the likelihood that such candidate
targets could have prognostic or therapeutic relevance.
We used oligonucleotide microarrays to examine the expression
of androgen regulated genes in normal human TZ prostate tissue
growing as xenografts in male SCID mice. Among genes with
androgen regulated expression that we identified, those with higher
expression in prostate relative to other tissues and those of the cell
surface or extracellular compartment have greatest potential to
serve as useful clinical biomarkers. The most promising candidates
wereculled with WebGestaltbioinformatics tools.Theexpressionof
these genes was screened using qRT-PCR analysis of cDNA pools
derived from BPH or prostate cancer tissues, to determine whether
expression was correlated with disease status.
When generating the androgen regulated gene lists, we used a
14 day time point in order to look for genes chronically up-
regulated in response to androgens. Genes identified as up-
regulated by androgens at this longest time point investigated were
also generally found to gradually increase levels at earlier time
points. Genes transiently up-regulated at earlier time points may
reflect genes indirectly induced during growth and differentiation,
and would likely be poor choices for markers of prostatic disease.
Tissue obtained as a surgical specimen from prostatectomy can
be subjected to prolonged blood supply interruption during
the surgical procedure, compromising RNA quality. The use of
xenografts allows the tissue to recover from damage induced
during surgery. Xenografts can be harvested rapidly with less
severe ischemia, thus allowing for the isolation of high quality
RNA. In addition to producing high quality tissue, this method vs
use of cell lines also allows us to study tissues with intact stromal-
epithelial interactions occurring in vivo. However, since the exact
ratios of stroma to epithelia are variable, genes identified as altered
at the RNA level in intact tissues could be related to changes in
epithelium, stroma or both. A weakness of the method is that the
tissue used for RNA extraction is destroyed, and even adjacent
tissues from the same patient may have markedly differing
stromal-epithelial ratios. Therefore, this approach requires subse-
quent validation by in situ hybridization or immunohistochemistry
to determine cell type specificity.
Several genes identified in our microarray analysis were
previously known to be regulated by androgens or involved in
prostatic disease. These included the up-regulated genes ACPP,
CXCL5, FGFBP1, FKBP11, KLK11, PTGDS, and TIMP1. CXCL5
was recently shown to be elevated in serum from patients with
BPH and may potentially distinguish between BPH and prostate
cancer among patients presenting with low serum PSA [43].
However, CXCL5 was also recently shown to promote prostate
cancer progression [44]. FGFBP1 is secreted from AR+ PC3 cells
in response to androgen [45], and is highly expressed in some
human prostate tumor cells and the proliferation of these cells was
dependent on these high expression levels [46]. FKBP11 expression
was up-regulated in mouse prostate by androgen [47]. Numerous
studies have investigated the use of serum levels of KLK11 as a
diagnostic marker to discriminate between prostate cancer and
BPH [48,49,50]. PTGDS derived prostaglandin D2 produced by
prostate stromal cells suppresses the growth of prostate tumor cells
through a PPARgamma-dependent mechanism [51]. TIMP1
levels were significantly elevated in blood plasma from prostate
cancer patients with metastases [52]. Such genes shown to be
androgen regulated and possibly showing altered protein levels in
sera of BPH patients are of interest as possible biomarkers in BPH.
However, substantial additional work is necessary to investigate
the possible role of these genes in the etiology of altered epithelial
and stromal proliferation in the TZ of BPH patients, their possible
contribution to the symptomatology of clinical BPH, and their
suitability as candidate biomarkers in the management of BPH.
We also identified genes in our microarray analysis that were
down-regulated by androgens. These included GLI1, ANNAT1
(annexin 1), BCL2,a n dCLIC4. Compatible with our observations,
expression of GLI1 was reported to increase in mouse prostate after
the withdrawal of androgen [41]. The expression of annexin 1 has
been reported to decrease in androgen stimulated prostate cancer
compared with benign prostatic epithelium [42]. Annexin 1 was
also reported to be highly over expressed in androgen-independent
LNCaP cells compared to androgen-dependent LNCaP cells [53].
BCL2 and CLIC4, have been reported to have anti-apoptotic, and
proapoptotic activities, respectively. Cardillo et al. found elevated
BCL2 expression in apoptosis resistant BPH following androgen
deprivation [54]. CLIC4 is involved in p53 mediated apoptosis [55].
At 14 days post androgen withdrawal the acute apoptotic phase of
tissue rearrangement in prostate xenografts has been largely
completed [22]. However, genes with decreased expression in
androgen stimulated TZ xenografts could be relevant in the
pathophysiology of androgen related abnormal glandular and
stromal growthinBPHand maybeimportant to investigate further.
Serum PSA commonly used for prostate cancer screening is
clearly related to prostate volume, which is increased as a
consequence of TZ expansion due to glandular and stromal
Table 5. Percentages of immunostaining scores from
duplicated samples separated by more than 1.
Protein Percentage Score Intensity Score
Stromal smoc1 3/43 (7.0) 1/41 (2.4)
calcyclin 4/43 (9.3) 1/17 (5.9)
timp2 3/43 (7.0) 0/41 (0.0)
Epithelial smoc1 7/43 (16.3) 0/42 (0.0)
calcyclin 0/43 (0.0) 0/6 (0.0)
fgf2 7/43 (16.3) 0/36 (0.0)
Tissue sections were scored on a scale of 0–7 for combined extent and intensity.
The ratios listed are the number of duplicate sections with scores differing by
more than 1, divided by the total number of sections scored. Intensity is scored
only on the samples for which percentage score is greater than 0.
doi:10.1371/journal.pone.0008384.t005
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either CaP or BPH are greatly needed. Fourteen genes were
identified as being highly elevated in BPH and had BPH/PCa
expression ratios of at least 5-fold (table 4). Of these genes, eight
have been previously implicated in BPH or prostate cancer,
and are also expressed extracellularly. These are EMP3, FGF2,
FGFBP1, IGF1, IGF2, TGFB3, TGFBR2, and TIMP2. FGF2
(fibroblast growth factor 2), IGF1 (insulin-like growth factor 1), and
IGF2 (insulin-like growth factor 2), have altered expression levels in
BPH and prostate cancer [56,57] and men with elevated IGF-1
serum levels have an increased risk for BPH [58]. IGF-II serum
levels increase the discrimination between BPH and prostate
Figure 3. Immunohistochemical staining by disease severity category. Percentage staining was scored on a scale of 0 to 4, where 0=no
staining, 1=less than 25%, 2=25% to 50%, 3=50% to 75%, and 4=75% to 100%. The intensity of staining was scored on a scale of 1 to 3, where
1=mild, 2=moderate, and 3=marked. For a sample yielding no staining, the intensity score was 0. When both stromal and epithelial staining was
present, scoring was done separately. For the samples for which two measurements were available, the average score was used to represent the
sample. To calculate a protein expression index, the percentage score was summed with the intensity score; the maximum score was 7. The
horizontal gray line represents within-group median.
doi:10.1371/journal.pone.0008384.g003
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[59]. TGFb3 (transforming growth-factor b3) is expressed in BPH
and normal prostate basal epithelial cells, but is reduced or absent
in prostate cancer [60].
Other genes identified from the microarray analysis as androgen
regulated and that were also highly expressed in pathologic BPH
tissues had not been previously implicated in BPH or prostate
cancer. These genes included F10 (upregulated 16-fold), LIPG,
SGCA and SMOC1 (upregulated 26-fold). Coagulation Factor X
(F10) is a serine protease that can be activated by cancer
procoagulant (CP), a cysteine protease produced by malignant
and embryonic tissues [61]. In addition to promoting blood
coagulation, coagulation proteases induce signal transduction
through the activation of G protein–coupled protease-activated
receptors (PARs) [62,63,64,65,66]. Additionally, activated Factor
X (Factor Xa) can mediate signal transduction via specific binding
to annexin 2 [67]. Endothelial lipase (LIPG) is involved in
lipoprotein metabolism and is elevated in inflammation [68,69].
SGCA (sarcoglycan alpha) encodes a component of the dystrophin-
glycoprotein complex (DGC) in striated muscle, which is critical to
the stability of muscle fiber membranes and to the linking of the
actin cytoskeleton to the extracellular matrix. [70,71]. Secreted
modular calcium-binding protein 1 (SMOC1) belongs to the BM-
40 family, which has been implicated in tissue remodeling,
angiogenesis and bone mineralization [72]. It is widely expressed
in many tissues and is a component of the basement membrane
[73]. The potential functional role of these genes, identified as
androgen regulated in intact human prostate TZ tissues as a novel
observation herein, in the pathologic glandular and stromal
hyperplasia characteristic of BPH remains to be elucidated. Their
spectrum of biologic and pathophysiologic functions is intriguing
and further demonstrates the potential of our investigational
approach to uncover unique target genes not identified in simple
models of cell lines or non-hormonally manipulated tissues.
Analysis of gene expression differences in RNA samples
extracted from intact tissues does not specifically allow for
localization of the increased or decreased altered genes to the
glandular and/or stromal compartments in TZ tissues, both of
which likely contribute fundamentally to evolution of BPH, nor
does it necessarily translate to altered levels of more biologically
relevant proteins. We examined the expression of a subset of genes
of interest in BPH tissues at the protein level by immunohisto-
chemistry (IHC), using a tissue microarray containing sections
with BPH pathologies ranging from minimal to severe. IHC
staining patterns were assessed semi-quantitatively for FGF2,
SMOC1, and TIMP2. The expression of FGF2 in BPH has been
previously reported by several groups [74,75,76]. This is the first
published report describing the expression of SMOC1 and TIMP2
in BPH tissue.
As all three of these genes have been found to have altered
expression in prostate cancer tissues and in much larger volumes of
BPH tissue (by qRT-PCR), they may very well play a role in BPH
progression, but based on results of IHC, it does not appear to be
simply based on uniform over-expression throughout the transition
zone.
The fact that expression arrays on intact human TZ tissues
xenografted into hormonally manipulated host mice identified
many genes well known to be androgen regulated validates our
approach. However, this method may still miss genes with low
expression levels that could be important in pathogenesis, although
such genes would seem less likely to make good biomarkers. When
we examined the expression of a subset of these highly expressed
genes from the microarray data by RT-PCR in BPH tissues, we
found several with elevated levels in BPH tissues relative to normal
controls. Our study confirms the known or postulated role of many
of these in prostate pathology, and identifies additional genes that
appear worthy of further investigation. The detailed analysis of
each of these genes will require substantial further investigation,
but may provide further insight into the molecular etiology of BPH
pathogenesis.
In summary, our results demonstrate the feasibility of using a
mouse xenograft model to characterize the gene expression
profiles of intact human prostate tissues in response to androgens.
The model has the unique advantage of maintaining intact
epithelial-stromal interactions during hormone manipulation,
cellular interactions which are likely crucial in the progressive
evolution of this androgen dependent pathologic condition. A
number of genes were identified that were regulated by androgens,
some that were previously well characterized, and many more
whose possible roles in prostate development and pathology
remain largely unknown. Additionally, a subset of these androgen
regulated genes were found to be over-expressed in RNA from
clinical BPH tissues, and the levels of many were found to correlate
with disease severity. Such knowledge may aid the discovery of
new diagnostic and therapeutic targets for the early detection and
treatment of BPH and prostate cancer.
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